Frequency and distribution of high-risk HPV genotypes according to age and origin in five regions of Paraguay
DOI:
https://doi.org/10.18004/Keywords:
genotyping, screening, high-risk human papillomavirusAbstract
Human papillomavirus (HPV) infection is common worldwide. High-risk (HR) HPV types are associated with cervical cancer and precancerous lesions that lead to other anogenital cancers and head and neck tumors. At least 15 types are carcinogenic: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82. Regional genetic diversity influences the pathogenicity of HPV. The objective was to compare the frequency and distribution of high-risk HPV genotypes by age group in more than 5,000 Paraguayan women with individual genotyping of high-risk HPV types 16 and 18 and other high-risk types in different regions of Paraguay among women aged 17 to 64 years. Cervical samples were collected from Paraguayan women (n = 5,272) from different regions of the country at cervical pathology clinics designated by the National Cervical Cancer Prevention Program from October 2014 to October 2018, who came in for a Papanicolaou (Pap) smear. Of the 5,272 samples tested, 1,071 were positive (20.3%). HR-HPV positivity was highest among women under 21 years of age (58%) and decreased with age, with a slight increase among those over 60 years of age. The highest HR-HPV positivity was observed in the capital (22.7%) and Presidente Hayes (20.4%); no significant differences were found between the capital/Central region and the rest of the country (p=0.2814). The high prevalence of HR-HPV infection observed provides relevant public health data for prioritizing cervical cancer screening and HPV vaccination.
Downloads
References
1. Wolf J, Kist LF, Pereira SB, Quessada MA, Petek H, Pille A, et al. Human papillomavirus infection: Epidemiology, biology, host interactions, cancer development, prevention, and therapeutics. Rev Med Virol. 2024; 34(3): e2537. doi: 10.1002/rmv.2537.
2. Muñoz-Bello JO, Carrillo-Garcia A, Lizano M. Epidemiology and Molecular Biology of HPV Variants in Cervical Cancer: The State of the Art in Mexico. Int J Mol Sci. 2022; 23 (15): 8566. doi: 10.3390/ijms23158566.
3. Tota JE, Shing JZ, Roberts JN, Anderson EM, Saah AJ, Harari A, et al. Epidemiological approaches to evaluate clinical unmasking of HPV-associated cervical lesions in the HPV vaccination era. Int J Cancer. 2026; 158(4): 847-857. doi: 10.1002/ijc.70119.
4. Włoszek E, Krupa K, Skrok E, Budzik MP, Deptała A, Badowska-Kozakiewicz A, et al. HPV and cervical cancer-biology, prevention, and treatment updates. Curr Oncol. 2025; 32(3): 122. doi: 10.3390/curroncol32030122.
5. Jain M, Yadav D, Jarouliya U, Chavda V, Yadav AK, Chaurasia B, et al. Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis. Pathogens. 2023; 12 (12): 1380. doi: 10.3390/pathogens12121380.
6. Ramírez AT, Valls J, Baena A, Rojas FD, Villagra V, Herrero R; ESTAMPA Study Group. Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA study. Lancet Reg Health Am. 2023; 26: 100593. doi: 10.1016/j.lana.2023.100593.
7. Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020; 70(5): 321-346. doi: 10.3322/caac.21628.
8. Ministerio de Salud Pública y Bienestar Social. Manual nacional de normas y procedimientos para la prevención y el control del cáncer del tracto genital inferior femenino. Asunción: MSPBS, Cooperación Española; 2023. ISBN 978-99925-11-05-3.
9. International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today. Estimated age-standardized cancer incidence, mortality and prevalence worldwide in 2022 [Internet]. Lyon: IARC; 2022 [citado abril de 2026]. Disponible en: https://gco.iarc.who.int/today/
10. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263. doi: 10.3322/caac.21834.
11. Sichero L, Picconi MA, Villa LL. The contribution of Latin American research to HPV epidemiology and natural history knowledge. Braz J Med Biol Res. 2020; 53(2): e9560. doi: 10.1590/1414-431X20199560.
12. Bobadilla ML, Zorrilla ME, Villagra V, Olmedo G, Roscher G, Franco F, et al. Detección molecular del virus papiloma humano de alto riesgo oncogénico en muestras cervicales. Laboratorio Central de Salud Pública: primeros resultados. Mem Inst Investig Cienc Salud. 2015; 13(1): 17-23. doi: 10.18004/Mem.iics/1812-9528/2015.013(01)17-023.
13. Villagra V, Langjahr P, Bobadilla ML, Olmedo B, Maldonado N. Comparación de técnicas moleculares de detección del virus del papiloma humano en muestras cervicales de mujeres paraguayas. Mem Inst Investig Cienc Salud. 2024; 22(1): e22122405. doi: 10.18004/mem.iics/1812-9528/2024.e22122405.
14. Husain RS, Ramakrishnan V. Global Variation of Human Papillomavirus Genotypes and Selected Genes Involved in Cervical Malignancies. Ann Glob Health. 2015; 81(5): 675-83. doi: 10.1016/j.aogh.2015.08.026.
15. Colpani V, Soares Falcetta F, Bacelo Bidinotto A, Kops NL, et al. Prevalence of human papillomavirus (HPV) in Brazil: A systematic review and meta-analysis. PLoS One. 2020; 15(2): e0229154. doi: 10.1371/journal.pone.0229154.
16. Rego RM, Vale DB, Campos CS, Vasconcelos L, Campos E, Lima HCL, et al. Age distribution of high-risk HPV infection and cervical lesions in an unvaccinated adult Brazilian population within an organized screening program. Sci Rep. 2026; 16(1): 4453. doi: 10.1038/s41598-025-34501-6.
17. Torres-Roman JS, Ronceros-Cardenas L, Valcarcel B, Bazalar-Palacios J, Ybaseta-Medina J, Carioli G, et al. Cervical cancer mortality among young women in Latin America and the Caribbean: trend analysis from 1997 to 2030. BMC Public Health. 2022; 22(1): 113. doi: 10.1186/s12889-021-12413-0.
18. Kasamatsu E, Rodríguez Riveros MI, Soilan AM, Ortega M, Mongelós P, Páez M, et al. Factors associated with high-risk human papillomavirus infection and high-grade cervical neoplasia: a population-based study in Paraguay. PLoS One. 2019; 14(6): e0218016. doi: 10.1371/journal.pone.0218016.
19. Giménez Caballero E, Rodríguez Zuccolillo JC, Peralta Garay N, Barrios R, Martínez Acosta P, Araujo Quevedo J, et al. Factores que limitan la descentralización del Sistema Nacional de Salud del Paraguay. An Fac Cienc Méd (Asunción). 2019; 52(2): 39-48. doi: 10.18004/anales/2019.052(02)39-048.
20. Mendoza LP, Arbiza J, Páez M, Kasamatsu E, Castro A, Giménez G, et al. Características clínico-demográficas y tipificación del virus de papiloma humano en mujeres paraguayas con citologías negativas para lesión escamosa intraepitelial. Mem Inst Investig Cienc Salud. 2012; 10(1): 46-55. Disponible en: http://scielo.iics.una.py/scielo.php?script=sci_arttext&pid=S1812-95282012000100006&lng=en
21. Godoy LR, Possati-Resende JC, Guimarães YM, Pedrão PG, Dos Reis R, Longatto-Filho A. Implementation of HPV Tests in Latin America: What We Learned; What Should We Have Learned, and What Can We Do Better? Cancers (Basel). 2022; 14(11): 2612. doi: 10.3390/cancers14112612.
22. Correa RM, Baena A, Valls J, Colucci MC, Mendoza L, Rol M, et al. Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America. PLoS One. 2022; 17(7): e0272205. doi: 10.1371/journal.pone.0272205.
23. Mongelos P, Mendoza LP, Rodríguez-Riveros I, Castro A, Gimenez G, Araujo P, et al. Distribution of human papillomavirus (HPV) genotypes and bacterial vaginosis presence in cervical samples from Paraguayan indigenous. Int J Infect Dis. 2015; 39: 44-9. doi: 10.1016/j.ijid.2015.08.007.
24. Grupo Sunu de Acción Cultural; Tierra Viva a los Pueblos Indígenas del Chaco. Monitoreo de la implementación del sistema de protección social en comunidades indígenas del Paraguay [Internet]. Asunción: Tierra Viva; 2025 [citado marzo de 2026]. Disponible en: https://www.tierraviva.org.py/wp-content/uploads/2025/12/Resumen-monitoreo-version-web.pdf
25. Bobadilla ML, Villagra V, Ortiz V, Deluca G, de Paula VS. High prevalence and co-infection of high-risk Human Papillomavirus genotypes among unvaccinated young women from Paraguay. PLoS One. 2023; 18(4): e0283542. doi: 10.1371/journal.pone.0283542.
26. Martins TR, Witkin SS, de Oliveira RL, Gadelha JGS, Assunção J, Albuquerque Alves I, et al. Evaluation and Recommendations to Modernize Cervical Cancer Detection and Prevention Programs in Brazil: Challenges and Opportunities - A Narrative Review. Acta Cytol. 2026; 70(4): 403-416. doi: 10.1159/000550725.
27. Bobadilla ML, Villagra V, Castro H, von Horoch M, Araya S, Deluca G, et al. Human Papillomavirus (HPV) Infection and Risk Behavior in Vaccinated and Non-Vaccinated Paraguayan Young Women. Pathogens. 2024; 13(3): 209. doi: 10.3390/pathogens13030209.
28. Hamid MKI, Hasneen S, Lima AK, Shawon SR, Shahriar M, Anjum R. Cervical cancer trends, HPV vaccine utilization, and screening in low- and lower-middle-income countries: an updated review. Ther Adv Vaccines Immunother. 2025; 13: 25151355251356646. doi: 10.1177/25151355251356646.
29. Rakhat A, Aimagambetova G. Cervical Cancer Screening in Transition: Global Challenges and Local Realities. Int J Womens Health. 2026; 18: 607741. doi: 10.2147/IJWH.S607741.
Published
Issue
Section
License
Copyright (c) 2026 Memorias del Instituto de Investigaciones en Ciencias de la Salud

This work is licensed under a Creative Commons Attribution 4.0 International License.



Submissions open year-round. Articles in English are encouraged; Spanish is also accepted.





